Key result
Neurohumoral antagonists reduce mortality, hospitalizations, and adverse remodeling across heart failure pathways.
This comprehensive review summarizes the pathophysiological role of sympathetic, RAAS, and vasopressin activation in heart failure and details the clinical evidence supporting neurohumoral blockade and biomarker-guided risk stratification.
Answers are grounded in this paper and cite their sources.
Supports neurohumoral blockade as foundational in heart failure; leaves open optimization of multi-pathway combinations.
In patients with heart failure (HF), the neuroendocrine systems of the sympathetic nervous system (SNS), the renin-angiotensin-aldosterone system (RAAS) and the arginine vasopressin (AVP) system, are activated to various degrees producing often-observed tachycardia and concomitant increased systemic vascular resistance. Furthermore, sustained neurohormonal activation plays a key role in the progression of HF and may be responsible for the pathogenetic mechanisms leading to the perpetuation of the pathophysiology and worsening of the HF signs and symptoms. There are biomarkers of activation of these neurohormonal pathways, such as the natriuretic peptides, catecholamine levels and neprilysin and various newer ones, which may be employed to better understand the mechanisms of HF drugs and also aid in defining the subgroups of patients who might benefit from specific therapies, irrespective of the degree of left ventricular dysfunction. These therapies are directed against these neurohumoral systems (neurohumoral antagonists) and classically comprise beta blockers, angiotensin-converting enzyme (ACE) inhibitors/angiotensin receptor blockers and vaptans. Recently, the RAAS blockade has been refined by the introduction of the angiotensin receptor-neprilysin inhibitor (ARNI) sacubitril/valsartan, which combines the RAAS inhibition and neprilysin blocking, enhancing the actions of natriuretic peptides. All these issues relating to the neurohumoral activation in HF are herein reviewed, and the underlying mechanisms are pictorially illustrated.
No takes yet. Share an insight, caveat, or question.
Antonis S. Manolis (2023) conducted a review in Heart Failure. Neurohumoral antagonists (beta blockers, ACE inhibitors, ARBs, MRAs, ARNI, vaptans, SGLT2 inhibitors) was evaluated. Neurohumoral antagonists targeting the sympathetic nervous system, RAAS, and natriuretic peptide pathways reduce mortality, hospitalizations, and adverse remodeling in heart failure.
Synapse has enriched 10 related papers. Consider them for comparative context: